Guillain Barre syndrome associated with COVID-19 infection: A case report

Sedaghat, Zahra; Karimi, Narges

doi:10.1016/j.jocn.2020.04.062

Cited by 499 publications

(514 citation statements)

References 13 publications

(21 reference statements)

Supporting

Mentioning

466

Contrasting

Unclassified

Order By: Relevance

“…reported. [4][5][6][7][8] All patients had fever and respiratory symptoms 5 to 10 days before the onset of the neurological symptoms, one of them had ongoing fever and poor general condition. The electrodiagnostic findings were consistent with an axonal variant of GBS in four out of nine patients.…”

Section: Nine Cases Of Gbs In Patients With Covid-19 Have Been Recentlymentioning

confidence: 99%

See 1 more Smart Citation

Guillain‐Barré syndrome during SARS‐CoV‐2 pandemic: A case report and review of recent literature

Scheidl¹,

Canseco²,

Hadji-Naumov³

et al. 2020

J Peripheral Nervous Sys

181

187

View full text Add to dashboard Cite

Acute demyelinating inflammatory polyneuropathy (AIDP) is the most common type of Guillain-Barré syndrome (GBS) in Europe, following several viral and bacterial infections. Data on AIDP-patients associated with SARS-CoV-2 (coronavirus-2) infection are scarce. We describe the case of a 54-years-old Caucasian female patient with typical clinical and electrophysiological manifestations of AIDP, who was reported positive with PCR for SARS-CoV-2, 3 weeks prior to onset of the neurological symptoms. She did not experience a preceding fever or respiratory symptoms, but a transient loss of smell and taste. At the admission to our neurological department, a progressive proximally pronounced paraparesis, areflexia, and sensory loss with tingling of all extremities were found, which began 10 days before. The modified Erasmus Giullain-Barré Syndrome outcome score (mEGOS) was 3/9 at admission and 1/12 at day 7 of hospitalization. The electrophysiological assessment proved a segmental demyelinating polyneuropathy and cerebrospinal fluid examination showed an albuminocytologic dissociation. The neurological symptoms improved significantly during treatment with immunoglobulins. Our case draws attention to the occurrence of GBS also in patients with COVID-19 (coronavirus disease 2019), who did not experience respiratory or general symptoms. It emphasizes that SARS-CoV-2 induces immunological processes, regardless from the lack of prodromic symptoms. However, it is likely that there is a connection between the severity of the respiratory syndrome and further neurological consequences.

show abstract

Section: Nine Cases Of Gbs In Patients With Covid-19 Have Been Recentlymentioning

confidence: 99%

“…4 tions, which is often fatal for patients with COVID-19. 1,2,4,5 It is likely, that these immunological processes are responsible for the major part of the organ manifestations, including the neurological complications.…”

mentioning

confidence: 99%

Guillain‐Barré syndrome during SARS‐CoV‐2 pandemic: A case report and review of recent literature

Scheidl¹,

Canseco²,

Hadji-Naumov³

et al. 2020

J Peripheral Nervous Sys

181

187

View full text Add to dashboard Cite

show abstract

“…Clinical symptoms of COVID-19 patients include upper respiratory tract infection with fever, dry cough, and dyspnea, indicating that the respiratory tract is the first target (2). However, emerging case reports showed that patients infected with SARS-CoV-2 suffered a sudden and complete loss of the olfactory function, stroke, and other severe neurological symptoms (3)(4)(5)(6)(7). All of these indicate that SARS-CoV-2 is neurotropic and could infect the central nervous system (CNS) (8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 targets cortical neurons of 3D human brain organoids and shows neurodegeneration-like effects

Gopalakrishnan

Ramani

Mueller

et al. 2020

Preprint

View full text Add to dashboard Cite

COVID-19 pandemic caused by SARS-CoV-2 infection is a public health emergency. COVID-19 typically exhibits respiratory illness. Unexpectedly, emerging clinical reports indicate that neurological symptoms continue to rise, suggesting detrimental effects of SARS-CoV-2 on the central nervous system (CNS). Here, we show that a Düsseldorf isolate of SARS-CoV-2 enters 3D human brain organoids within two days of exposure. Using COVID-19 convalescent serum, we identified that SARS-CoV-2 preferably targets soma of cortical neurons but not neural stem cells, the target cell type of ZIKA virus. Imaging cortical neurons of organoids reveal that SARS-CoV-2 exposure is associated with missorted Tau from axons to soma, hyperphosphorylation, and apparent neuronal death. Surprisingly, SARS-CoV-2 co-localizes specifically with Tau phosphorylated at Threonine-231 in the soma, indicative of early neurodegeneration-like effects. Our studies, therefore, provide initial insights into the impact of SARS-CoV-2 as a neurotropic virus and emphasize that brain organoids could model CNS pathologies of COVID-19.

show abstract

“…Acute neuropathy in patients with Covid-19 is increasingly reported [1][2][3][4][5][6]. We present another case with fulminant polyradiculoneuritis, suggestive of Guillain-Barré-syndrome (GBS), leading to a locked-in syndrome with corresponding generalized nerve root contrast enhancement on MRI.…”

Section: Introductionmentioning

confidence: 89%